Analyst Conference Summary

biotechnology

conference date: November 11, 2026 @ 5:30 AM Pacific Time
for quarter ending: June 30, 2026 (second quarter, Q2)

Forward-looking statements

Overview:

Basic data (GAAP):

Revenue was zero.

Net income, diluted, was negative $ million, down sequentially from negative $3.1 million, and up from negative $ million year-earlier.

EPS (earnings per share), diluted, was negative $, down sequentially from negative $0.62, and up from negative $ year-earlier.

Guidance:

Conference Highlights:

Dr. Jennifer Buell, President and CEO of MiNK said: ""

.

Current externally supported programs include its graft-versus-host disease program supported by NIH STTR funding and the Mary Gooze philanthropic award.

Strategic discussions to advance agent-797 in end stage pulmonary fibrosis (IPF) are actively underway.

MiNK has not confirmed some announcements of clinical partnerships by others, but will keep investors informed of developments.

Mink Therapeutics ended the quarter with a cash balance of $ million, down sequentially from $8.8 million. $ million cashed used in operations.

Operating expenses were not given. $ million, consisting of: R&D $ million; G&A $ million. Change in fair value $ million. Other expense $ million.

Q&A selective summary:

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: